Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 16.78
(0.78%)
CNY 16.78
(0.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 253.19 Million CNY | 24.66% |
| 2022 | 210.19 Million CNY | 38.54% |
| 2021 | 148.27 Million CNY | -21.91% |
| 2020 | 193.82 Million CNY | -25.3% |
| 2019 | 258.48 Million CNY | 31.01% |
| 2018 | 193.43 Million CNY | 35.95% |
| 2017 | 142.49 Million CNY | -7.21% |
| 2016 | 149.31 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 41.84 Million CNY | -26.79% |
| 2024 Q1 | 33.99 Million CNY | -10.03% |
| 2024 Q3 | 17.48 Million CNY | -62.16% |
| 2023 Q4 | 40.51 Million CNY | 1.05% |
| 2023 FY | - CNY | 24.66% |
| 2023 Q3 | 40.09 Million CNY | 13.84% |
| 2023 Q2 | 35.22 Million CNY | -2.68% |
| 2023 Q1 | 36.19 Million CNY | -15.94% |
| 2022 FY | - CNY | 38.54% |
| 2022 Q3 | 26.19 Million CNY | 27.86% |
| 2022 Q2 | 20.48 Million CNY | -27.18% |
| 2022 Q1 | 28.13 Million CNY | 26.77% |
| 2022 Q4 | 43.05 Million CNY | 64.36% |
| 2021 Q2 | 36.55 Million CNY | 23.55% |
| 2021 Q1 | 29.58 Million CNY | 9.06% |
| 2021 FY | - CNY | -21.91% |
| 2021 Q4 | 22.19 Million CNY | 567.44% |
| 2021 Q3 | -4.74 Million CNY | -112.99% |
| 2020 FY | - CNY | -25.3% |
| 2020 Q4 | 27.13 Million CNY | -25.07% |
| 2020 Q3 | 36.2 Million CNY | -61.48% |
| 2020 Q2 | 94.01 Million CNY | 1132.28% |
| 2020 Q1 | 7.62 Million CNY | -84.92% |
| 2019 Q4 | 50.59 Million CNY | 1.37% |
| 2019 Q3 | 49.91 Million CNY | 0.0% |
| 2019 FY | - CNY | 31.01% |
| 2018 FY | - CNY | 35.95% |
| 2017 FY | - CNY | -7.21% |
| 2016 FY | - CNY | 0.0% |